AlphAIAlphAI — Financial news for AI agents
barchart.comAUG 262 min read$STE

STERIS Stock Outlook: Is Wall Street Bullish or Bearish?

STERIS plc (STE), a provider of infection prevention products, reported mixed Q2 2026 earnings with revenue of $1.5B, up 7.3% YoY, and adjusted EPS of $2.59, beating estimates. Free cash flow margin declined to 18.7% from 23.5% YoY. Analysts expect EPS to rise 9.1% for the year ending March 2027. The stock has underperformed the S&P 500 and XLV ETF over the past year and 2026. Analysts' consensus is 'Moderate Buy' with a mean price target of $263.75, implying 11.6% upside.

Original reporting
barchart.com
Published Aug 26, 2026, 10:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 11:39 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
STERIS Stock Outlook: Is Wall Street Bullish or Bearish? — source image
Source · barchart.com
Decision brief

The 30-second read

$STENeutralHigh
01

Why it matters

Earnings beat may trigger short‑term buying, but free cash flow weakness could limit upside.

02

Market read

Steris earnings provide a modest catalyst for the healthcare equipment sector, with limited broader market impact.

03

What to watch

Potential impact of upcoming regulatory changes on sterilization products not discussed.

Relevance 8/10Novelty 8/10Timing: post‑earnings Aug 5 release

Background

Steris is a mid‑cap provider of infection prevention and sterilization solutions with a $23.1B market cap.

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

Q2 2026 earnings: revenue $1.5B (+7.3% YoY), adjusted EPS $2.59 beating estimates; free cash flow margin fell to 18.7%.

Expected impact

Potential modest upside of 5‑10% if investors focus on earnings beat and target raise.

Evidence & confidence

Earnings beat supports short‑term rally, but margin decline tempers enthusiasm.

Market effects

Sector

Highlights mixed performance in healthcare equipment sector; peers may see similar valuation pressure.

Regional

U.S. healthcare equipment stocks could see modest re‑rating.

Global

Limited to U.S. and international Steris customers; no broad macro effect.

Counterpoint

What could challenge this read

Margin compression may signal deeper operational issues, suggesting caution despite earnings beat.

Key entities

  • Company
    Steris plc

    Infection prevention products and services provider.

  • Analyst
    KeyBanc

    Maintained Buy rating and set $269 price target.

Read at source← All news

Related articles

AUG 9
$STEMed

STERIS Q1 Earnings Call Highlights

STERIS (NYSE:STE) reported Q1 Healthcare capital equipment revenue up 1% and ending backlog at $444 million, while capital equipment orders rose 4%. Healthcare EBIT margin increased 60 bps to 24.8%. Life Sciences organic revenue grew 8% and EBIT margin fell to 42.1%. STERIS plans a $600 million North Carolina chemistry center, with FY2027 EPS guidance $11.10 to $11.30.

finance.yahoo.com4 min
AUG 5
$STEMed

STERIS Announces Financial Results for Fiscal 2027 First Quarter

STERIS plc (STE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STERIS Announces Financial Results for Fiscal 2027 First Quarter • Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% • Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share i

SEC EDGAR 8-K6 min
MAY 27
$STEMedAI 8/10

Are Wall Street Analysts Predicting STERIS Stock Will Climb or Sink?

STERIS plc (STE) has lagged the market, falling 11.2% over the past year versus a 27.9% S&P 500 gain, and is down 14.6% in 2026 YTD. After Q4 results on May 11 (revenue $1.6B, +7.3% YoY; adjusted EPS $2.83, +3.3%), analysts expect FY2027 EPS of $11.18 (+9.9%). Consensus is “Moderate Buy” (5 “Strong Buy,” 3 “Hold”); KeyBanc cut its target to $269.

finance.yahoo.com4 min
OCT 8
$WSMedAI 8/10

Worthington Steel Inc (WS) (Q1 2027) Earnings Call Highlights: Kloeckner Acquisition Drives

Worthington Steel Inc (WS) reported Q1 2027 earnings with $954M net sales, up 9% YoY, and adjusted EBITDA of $111M. The Kloeckner acquisition expanded operations but resulted in a net loss of $7M due to higher interest and purchase accounting impacts. Automotive and agriculture shipments grew, while energy and construction declined. Net debt stands at $1.9B. Management expects synergy benefits post-integration.

finance.yahoo.com3 min
OCT 8
$TSCOMedAI 8/10

Tesco lifts low end of profit guidance as first-half profit rises 6.5%

Tesco raised its full-year profit guidance after reporting a 6.5% rise in first-half adjusted operating profit to £1.78 billion. The company now expects £3.15 billion to £3.30 billion in adjusted operating profit. Sales rose 2.0% to £33.8 billion, and earnings per share increased 12.2% to 17.3p. Tesco increased its share buyback and capital expenditure guidance, with online sales growing 8%.

investing.com1 min